Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

3SBio Pays $85 Million to Acquire Zhejiang Washeng Pharma

publication date: Jul 24, 2015
3SBio of Shenyang acquired Zhejiang Wansheng Pharma, a small molecule drugmaker, for $85 million. Wansheng is approved to market 55 products in the areas of oncology, diabetes, cardiovascular and dermatology. It also has 13 GMP production lines. The transaction is priced at 20 times Wansheng's earnings and slightly less than two times sales. According to 3SBio, which is known mainly as a biologics company, the acquisition provides a manufacturing facility for 3SBio's 12 small-molecule pipeline drugs and adds depth to its portfolio of nephrology and oncology offerings. More details....

Stock Symbol: (HK:1530)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital